MedTrace Logo

Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

NCT04884308 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-02-10

Study results available
· View outcomes & findings →

Summary

This is pilot study of the immunologic effects of intradermal Bacille Calmette-Guerin (BCG) vaccination of adults with cystic fibrosis (CF), non-CF bronchiectasis (NCFB), and healthy volunteers.

Conditions

Interventions

BIOLOGICAL

BCG TICE Vaccine

Intradermal vaccination with BCG TICE

Sponsors & Collaborators

Principal Investigators

  • Noah Lecthzin, MD, MHS · Johns Hopkins University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-28
Primary Completion
2023-12-30
Completion
2023-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04884308 on ClinicalTrials.gov